Incretin hormones, gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), both play important roles in triggering the pancreas to secrete insulin to achieve normal glucose homeostasis, however, for people with diabetes, the pancreas becomes less responsive to incretins (predominately to GIP)
It works by: Slowing gastric emptying, helping you feel fuller longer Suppressing appetite and reducing cravings, especially for high-calorie, processed foods Improving blood sugar control, even in non-diabetic patients Targeting the brains hunger signals, which reduces snacking and emotional eating Originally developed to treat type 2 diabetes under the brand name Ozempic, semaglutide is now FDA-approved for chronic weight management under the name Wegovy
This eliminates injection site variability as a factor when evaluating dose effectiveness
The doctor or nurse may pinch your skin to pull the subcutaneous tissue away from the muscle
What changed in this update
